Option chain shows key data for Bio-Path Holdings's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Bio-Path Holdings.

Bio-Path Holdings (OTC:BPTH) Stock, Option Chain

Bio-Path Hldgs

Bio-Path Holdings

Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of a Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.

Medtronic, Fluor And 3 Stocks To Watch Heading Into Tuesday

Earnings

Equities

News

Eurozone

Commodities

Markets

Trading Ideas

BPTH

HCTI

PRFX

PTPI

SEPN

US Stocks Mixed; NY State Business Activity Rises In February

jobless shutter

LITM

OMER

TPET

Nasdaq Jumps 100 Points, US Initial Jobless Claims Decline

Photo by solarseven on Shutterstock

Movers

Bio-Path Holdings, Inc. (NASDAQ: BPTH) shares are surging Thursday following the company&#39;s announcement of encouraging preclinical results for BP1001-A, a potential treatment for obesity and Type 2 diabetes. Here&#39;s what you need to know.

Bio-Path Holdings Shares Were On The Rise: What&#39;s Going On?

BIO-PATH HOLDINGS INC by Bio-Path Holdings, Inc.

Bio-Path Holdings Inc

Analyst Ratings

Press Releases

Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity

Early Santa Claus Rally Highlights Power Nickel Inc. (TSXV: PNPN) and Other Stocks to Watch Now!

General

Bio-Path Holdings Provides 2025 Clinical and Operational Update

Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia

Bio-Path Holdings Provides Key Clinical Updates

Legal

Bio-Path Holdings Expands Global Patent Portfolio

Health Care

Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients

Bio-Path Holdings Reports Full Year 2024 Financial Results

Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients

Comments

Bio-Path Holdings

Bio-Path Holdings (BPTH) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell